Daltroban (BM 13505, SKF 96148), a specific thromboxane A2 receptor antagonist, was studied as an antithrombotic agent. Daltroban increases intracellular calcium in vascular smooth muscle cells. Daltroban shows a protective effect in reperfusion injury. The drug was licensed to Smith Kline Beecham and underwent phase III clinical trials in the UK and Germany as an antithrombotic agent but did not enter clinical trials in the USA. Besides, вaltroban was investigated in patients with an ischemic heart disorder. However, the development of daltroban has been discontinued.
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist that increases intracellular calcium ions in vascular smooth muscle cells and protects against reperfusion injury after myocardial ischaemia but not in coronary artery endothelial cells. Daltroban may also be useful in the treatment of patients with COPD-related pulmonary hypertension.
